Insider Selling: West Pharmaceutical Services Inc. (NYSE:WST) SVP Sells $3,842,008.56 in Stock

West Pharmaceutical Services Inc. (NYSE:WST) SVP David A. Montecalvo sold 14,508 shares of the firm’s stock in a transaction on Tuesday, July 28th. The stock was sold at an average price of $264.82, for a total value of $3,842,008.56. Following the completion of the transaction, the senior vice president now directly owns 15,732 shares in the company, valued at $4,166,148.24. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

NYSE:WST opened at $268.87 on Friday. The company has a quick ratio of 2.11, a current ratio of 2.96 and a debt-to-equity ratio of 0.20. The business’s 50-day simple moving average is $229.94 and its two-hundred day simple moving average is $185.69. The stock has a market cap of $19.86 billion, a PE ratio of 70.94, a P/E/G ratio of 3.63 and a beta of 1.13. West Pharmaceutical Services Inc. has a 52 week low of $124.53 and a 52 week high of $273.78.

West Pharmaceutical Services (NYSE:WST) last posted its quarterly earnings results on Thursday, July 23rd. The medical instruments supplier reported $1.25 EPS for the quarter, beating the Zacks’ consensus estimate of $0.91 by $0.34. The business had revenue of $527.20 million for the quarter, compared to analysts’ expectations of $496.09 million. West Pharmaceutical Services had a return on equity of 19.01% and a net margin of 14.69%. The business’s quarterly revenue was up 12.2% on a year-over-year basis. During the same period last year, the firm earned $0.89 earnings per share. Sell-side analysts anticipate that West Pharmaceutical Services Inc. will post 4.27 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, August 5th. Shareholders of record on Wednesday, July 29th will be issued a dividend of $0.16 per share. The ex-dividend date of this dividend is Tuesday, July 28th. This represents a $0.64 dividend on an annualized basis and a yield of 0.24%. West Pharmaceutical Services’s dividend payout ratio is presently 19.75%.

A number of brokerages recently commented on WST. Zacks Investment Research reaffirmed a “buy” rating and issued a $219.00 target price on shares of West Pharmaceutical Services in a report on Sunday, May 3rd. Bank of America raised West Pharmaceutical Services from a “neutral” rating to a “buy” rating and set a $280.00 target price on the stock in a report on Tuesday, July 21st. Finally, BofA Securities raised West Pharmaceutical Services from a “neutral” rating to a “buy” rating and set a $280.00 price target on the stock in a report on Tuesday, July 21st.

Hedge funds have recently modified their holdings of the company. Shine Investment Advisory Services Inc. boosted its stake in West Pharmaceutical Services by 24.6% during the second quarter. Shine Investment Advisory Services Inc. now owns 208 shares of the medical instruments supplier’s stock valued at $47,000 after buying an additional 41 shares during the last quarter. Parallel Advisors LLC boosted its position in shares of West Pharmaceutical Services by 54.9% during the 2nd quarter. Parallel Advisors LLC now owns 127 shares of the medical instruments supplier’s stock valued at $28,000 after acquiring an additional 45 shares during the last quarter. Signaturefd LLC boosted its position in shares of West Pharmaceutical Services by 47.5% during the 2nd quarter. Signaturefd LLC now owns 149 shares of the medical instruments supplier’s stock valued at $34,000 after acquiring an additional 48 shares during the last quarter. Lido Advisors LLC boosted its position in shares of West Pharmaceutical Services by 6.4% during the 1st quarter. Lido Advisors LLC now owns 1,524 shares of the medical instruments supplier’s stock valued at $232,000 after acquiring an additional 91 shares during the last quarter. Finally, Beacon Investment Advisory Services Inc. boosted its position in shares of West Pharmaceutical Services by 2.3% during the 2nd quarter. Beacon Investment Advisory Services Inc. now owns 4,559 shares of the medical instruments supplier’s stock valued at $1,036,000 after acquiring an additional 104 shares during the last quarter. 90.59% of the stock is currently owned by hedge funds and other institutional investors.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc manufactures and sells containment and delivery systems for injectable drugs and healthcare products in the United States, Germany, France, Other European countries, South Korea, and internationally. The company operates through two segments, Proprietary Products and Contract-Manufactured Products.

Featured Article: Dow Jones Industrial Average (DJIA)

Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.